226 related articles for article (PubMed ID: 37212947)
1. Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC).
Chandnani N; Choudhari VS; Talukdar R; Rakshit S; Shanmugam G; Guchait S; Gupta I; George M; Sarkar K
Med Oncol; 2023 May; 40(7):185. PubMed ID: 37212947
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.
Chandnani N; Gupta I; Thakkar V; Sarkar K
Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922
[TBL] [Abstract][Full Text] [Related]
3. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
5. Polycomb recruitment at the Class II transactivator gene.
Boyd NH; Morgan JE; Greer SF
Mol Immunol; 2015 Oct; 67(2 Pt B):482-91. PubMed ID: 26283540
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Yin Yang 1 (YY1) Expression in T-Cell Subsets Differentiation and Their Functions: Implications in T Cell-Mediated Diseases.
Kosasih FR; Bonavida B
Crit Rev Immunol; 2019; 39(6):491-510. PubMed ID: 32421959
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
8. Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression.
Zang X; Gu J; Zhang J; Shi H; Hou S; Xu X; Chen Y; Zhang Y; Mao F; Qian H; Zhu T; Xu W; Zhang X
Cell Death Dis; 2020 Apr; 11(4):215. PubMed ID: 32242003
[TBL] [Abstract][Full Text] [Related]
9. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway.
Sun CC; Zhu W; Li SJ; Hu W; Zhang J; Zhuo Y; Zhang H; Wang J; Zhang Y; Huang SX; He QQ; Li DJ
Genome Med; 2020 Sep; 12(1):77. PubMed ID: 32878637
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
12. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
13. Association of Wiskott-Aldrich syndrome protein (WASp) in epigenetic regulation of B cell differentiation in non-small-cell lung cancer (NSCLC).
Chandnani N; Mandal A; Gupta I; Mukherjee O; Rakshit S; Shanmugam G; George M; Sarkar K
Med Oncol; 2023 Dec; 41(1):28. PubMed ID: 38146020
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EZH2 Ameliorates Sepsis Acute Lung Injury (SALI) and Non-Small-Cell Lung Cancer (NSCLC) Proliferation through the PD-L1 Pathway.
Wang Z; Guo Z; Wang X; Liao H; Chai Y; Wang Z; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552722
[TBL] [Abstract][Full Text] [Related]
15. YAP-Mediated Recruitment of YY1 and EZH2 Represses Transcription of Key Cell-Cycle Regulators.
Hoxha S; Shepard A; Troutman S; Diao H; Doherty JR; Janiszewska M; Witwicki RM; Pipkin ME; Ja WW; Kareta MS; Kissil JL
Cancer Res; 2020 Jun; 80(12):2512-2522. PubMed ID: 32409309
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
17. EZH2 deficiency attenuates Treg differentiation in rheumatoid arthritis.
Xiao XY; Li YT; Jiang X; Ji X; Lu X; Yang B; Wu LJ; Wang XH; Guo JB; Zhao LD; Fei YY; Yang HX; Zhang W; Zhang FC; Tang FL; Zhang JM; He W; Chen H; Zhang X
J Autoimmun; 2020 Mar; 108():102404. PubMed ID: 31952907
[TBL] [Abstract][Full Text] [Related]
18. Yin Yang 1-Induced Long Noncoding RNA DUXAP9 Drives the Progression of Oral Squamous Cell Carcinoma by Blocking CDK1-Mediated EZH2 Degradation.
Zhou W; Feng Y; Lin C; Chao CK; He Z; Zhao S; Xue J; Zhao XY; Cao W
Adv Sci (Weinh); 2023 Sep; 10(25):e2207549. PubMed ID: 37401236
[TBL] [Abstract][Full Text] [Related]
19. EZH2 as a Regulator of CD8+ T Cell Fate and Function.
Stairiker CJ; Thomas GD; Salek-Ardakani S
Front Immunol; 2020; 11():593203. PubMed ID: 33117406
[TBL] [Abstract][Full Text] [Related]
20. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
